Stonebrook Private Inc. Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

Stonebrook Private Inc. bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,053 shares of the medical research company’s stock, valued at approximately $706,000.

Other institutional investors also recently modified their holdings of the company. AdvisorNet Financial Inc raised its stake in shares of IQVIA by 327.6% in the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 95 shares during the last quarter. BKM Wealth Management LLC bought a new position in shares of IQVIA in the fourth quarter valued at approximately $32,000. Activest Wealth Management bought a new position in shares of IQVIA in the fourth quarter valued at approximately $35,000. CVA Family Office LLC bought a new position in shares of IQVIA in the fourth quarter valued at approximately $43,000. Finally, CoreFirst Bank & Trust bought a new position in IQVIA in the 3rd quarter worth approximately $44,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 0.4 %

Shares of IQV stock traded up $0.90 on Friday, hitting $234.88. The stock had a trading volume of 697,640 shares, compared to its average volume of 761,918. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The firm has a market cap of $42.63 billion, a P/E ratio of 32.22, a PEG ratio of 2.27 and a beta of 1.50. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12. The company has a fifty day moving average price of $245.28 and a two-hundred day moving average price of $223.17.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.82 by $0.02. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The company had revenue of $3.87 billion during the quarter, compared to analyst estimates of $3.80 billion. During the same quarter in the previous year, the business earned $2.54 EPS. The firm’s revenue was up 3.5% on a year-over-year basis. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.12 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the transaction, the insider now directly owns 20,836 shares of the company’s stock, valued at approximately $5,031,894. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the sale, the insider now directly owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $241.50, for a total transaction of $241,500.00. Following the sale, the insider now directly owns 20,836 shares in the company, valued at $5,031,894. The disclosure for this sale can be found here. Insiders sold 41,285 shares of company stock valued at $10,331,003 in the last quarter. Company insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on IQV shares. BTIG Research started coverage on shares of IQVIA in a research report on Tuesday, February 13th. They issued a “buy” rating and a $285.00 price objective for the company. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Leerink Partnrs restated an “outperform” rating on shares of IQVIA in a research report on Monday, February 26th. Guggenheim cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Finally, Evercore ISI boosted their price objective on shares of IQVIA from $255.00 to $265.00 and gave the stock a “market outperform” rating in a research report on Thursday, February 15th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $256.80.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.